Market Research Logo

Anesthetic Effect - Pipeline Review, H2 2016

Anesthetic Effect - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Anesthetic Effect - Pipeline Review, H2 2016’, provides an overview of the Anesthetic Effect pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
    • The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects
    • The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Anesthetic Effect
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Anesthetic Effect Overview
    Therapeutics Development
    Pipeline Products for Anesthetic Effect - Overview
    Pipeline Products for Anesthetic Effect - Comparative Analysis
    Anesthetic Effect - Therapeutics under Development by Companies
    Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes
    Anesthetic Effect - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Anesthetic Effect - Products under Development by Companies
    Anesthetic Effect - Products under Investigation by Universities/Institutes
    Anesthetic Effect - Companies Involved in Therapeutics Development
    Biolab Farmaceutica Ltda
    Drawbridge Pharmaceuticals Pty Ltd
    Expanesthetics Inc
    Jiangsu Hengrui Medicine Co., Ltd.
    Lipicard Technologies Limited
    NanoMedex Pharmaceuticals, Inc.
    Paion AG
    Phosphagenics Limited
    Physica Pharma
    Primex Pharmaceuticals Oy
    Proteus SA
    Sphaera Pharma Pvt. Ltd.
    Taiwan Liposome Company, Ltd.
    The Medicines Company
    Anesthetic Effect - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ABP-700 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADV-6209 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alphaxalone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bupivacaine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Carboetomidate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    gabafol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSK-3486 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LT-1121 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LT-1123 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Methoxycarbonyl Carboetomidate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Methoxycarbonyl Etomidate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    neosaxitoxin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PB-5109 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PHY-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    propofol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    propofol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    propofol microemulsion - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    remimazolam - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    remimazolam - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for General Anesthetic Effect - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for General Anesthetic Effect - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPR-819 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Anesthetic Effect - Dormant Projects
    Anesthetic Effect - Discontinued Products
    Anesthetic Effect - Product Development Milestones
    Featured News & Press Releases
    Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
    Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
    Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
    Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
    Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
    Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings
    Oct 22, 2015: The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting
    Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015
    Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
    Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
    Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
    Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion
    Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
    Oct 10, 2014: Paion Expects Ono’S Remimazolm Decision On Filing In Japan In November 2014
    Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Anesthetic Effect, H2 2016
    Number of Products under Development for Anesthetic Effect - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H2 2016
    Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2016
    Anesthetic Effect - Pipeline by Expanesthetics Inc, H2 2016
    Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
    Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H2 2016
    Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2016
    Anesthetic Effect - Pipeline by Paion AG, H2 2016
    Anesthetic Effect - Pipeline by Phosphagenics Limited, H2 2016
    Anesthetic Effect - Pipeline by Physica Pharma, H2 2016
    Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H2 2016
    Anesthetic Effect - Pipeline by Proteus SA, H2 2016
    Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016
    Anesthetic Effect - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
    Anesthetic Effect - Pipeline by The Medicines Company, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Anesthetic Effect - Dormant Projects, H2 2016
    Anesthetic Effect - Dormant Projects (Contd..1), H2 2016
    Anesthetic Effect - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Anesthetic Effect, H2 2016
    Number of Products under Development for Anesthetic Effect - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report